Evidence map›Paper›PMID 39563013›Full record

ArticleCNS neuroscience & therapeutics2024

Selective Inhibition of P2Y

Yiying Li, Weiping Wang, Jie Cai, Nan Feng, Shaofeng Xu, Ling Wang, Xiaoliang Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yiying LiState Key Laboratory of Bioactive Substances and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Weiping WangState Key Laboratory of Bioactive Substances and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jie CaiState Key Laboratory of Bioactive Substances and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Nan FengState Key Laboratory of Bioactive Substances and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shaofeng XuState Key Laboratory of Bioactive Substances and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ling WangState Key Laboratory of Bioactive Substances and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiaoliang WangState Key Laboratory of Bioactive Substances and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0002-0114-3906

Funding

Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study BZ0150Chinese Academy of Medical Sciences Initiative for Innovative Medicine 2021-I2M-1-028-1Natural Science Foundation of Hainan Province 821QN260Project of Hainan Association for Science and Technology of Youth Science and Talents QCXM202023
6 · The paper itself

Abstract

aimPotassium 2-(1-hydroxypentyl)-benzoate (dl-PHPB), puerarin and salvianolic acid B are three natural products or derivatives that can inhibit platelet aggregation. However, the mechanisms of dl-PHPB, puerarin and salvianolic acid B to inhibit platelet aggregation are still not clear.

methodHere, 2-methylthioadenosine diphosphate (2-MeSADP) was used as an inducer to confirm the effects of three drugs on platelet aggregation and illustrate the corresponding mechanisms.

resultThe results indicated that dl-PHPB, puerarin and salvianolic acid B significantly inhibited platelet aggregation both in vivo and in vitro. In addition, the content of IP

conclusionThese results suggested that dl-PHPB and puerarin inhibited platelet aggregation via targeting at P2Y

Indexed as

BenzofuransIsoflavonesPlatelet AggregationReceptors, Purinergic P2Y1Receptors, Purinergic P2Y12Signal TransductionAdenosine DiphosphateAnimalsCalciumCyclic AMPDepsidesHEK293 CellsHumansMalePlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsAdenosine DiphosphateBenzofuransCalciumCyclic AMPDepsidesIsoflavonesmethylthio-ADPPlatelet Aggregation InhibitorspuerarinPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y1Receptors, Purinergic P2Y12salvianolic acid BThionucleotidesP2Y1P2Y12platelets aggregationpotassium 2‐(1‐hydroxypentyl)‐benzoatepuerarinsalvianolic acid B

Identifiers

PMID39563013
PMCPMC11576485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.